Biocardia Stock Investor Sentiment

BCDA Stock  USD 2.28  0.09  3.80%   
About 57% of all Biocardia's investors are looking to take a long position. The analysis of the overall investor sentiment regarding Biocardia suggests that some traders are interested. The current market sentiment, together with Biocardia's historical and current headlines, can help investors time the market. In addition, many technical investors use Biocardia stock news signals to limit their universe of possible portfolio assets.
  

Biocardia Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Biocardia can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over a year ago at finance.yahoo.com         
BioCardia Reports First Quarter 2023 Business Highlights and Financial Results
Yahoo News
over a year ago at benzinga.com         
BioCardia Announces US Patent on Bone Marrow Derived Neurokinin-1 Receptor Positive Mesenchymal Stem...
benzinga news
over a year ago at zacks.com         
Intra-Cellular Therapies Reports Q1 Loss, Tops Revenue Estimates
zacks News
over a year ago at globenewswire.com         
BioCardia to Host Q1 2023 Financial Results and Corporate Update Conference Call on May 10, 2023
Macroaxis News: globenewswire.com
over a year ago at thelincolnianonline.com         
BioCardia, Inc. Sees Large Decline in Short Interest
news
over a year ago at benzinga.com         
BioCardia Presentations at Next Generation Cardiovascular Drug Development Summit Now Available
benzinga news
over a year ago at news.google.com         
Moderna Inc has fallen -3.77 percent in a Week, Should You Buy - InvestorsObserver
Google News at Macroaxis
over a year ago at news.google.com         
Is Immunitybio Inc Stock Worth a Buy Monday - InvestorsObserver
Google News at Macroaxis
over a year ago at news.google.com         
CytoMed Therapeutics prices 9.6M offering - Seeking Alpha
Google News at Macroaxis
over a year ago at news.google.com         
Do Traders Think Arcus Biosciences Inc Can Keep Climbing Thursday - InvestorsObserver
Google News at Macroaxis
over a year ago at insidermonkey.com         
BioCardia, Inc. Q4 2022 Earnings Call Transcript
insidermonkey News
over a year ago at finance.yahoo.com         
Were Keeping An Eye On BioCardias Cash Burn Rate
Yahoo News
over a year ago at investing.com         
Biocardia earnings beat, revenue fell short of estimates
Investing News at Macroaxis
over a year ago at finance.yahoo.com         
BioCardia Reports Fourth Quarter and Full Year 2022 Business Highlights and Financial Results
Yahoo News
over a year ago at finance.yahoo.com         
BC Dentists Applaud Expansion of Dental Care in Federal Budget
Yahoo News
Far too much social signal, news, headlines, and media speculation about Biocardia that are available to investors today. That information is available publicly through Biocardia media outlets and privately through word of mouth or via Biocardia internal channels. However, regardless of the origin, that massive amount of Biocardia data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Biocardia news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Biocardia relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Biocardia's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Biocardia alpha.

Biocardia Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Allen Jim L. of 50000 shares of Biocardia at 3.0 subject to Rule 16b-3
09/03/2024
2
Acquisition by Peter Altman of 1000 shares of Biocardia at 2.4877 subject to Rule 16b-3
09/13/2024
3
Acquisition by Allen Jim L. of 829 shares of Biocardia at 2.65 subject to Rule 16b-3
10/11/2024
4
Short Interest in BioCardia, Inc. Decreases By 12.6
10/15/2024
5
BioCardia Completes Phase III Randomized Double-Blind Controlled Trialof Autologous Cell Therapy for Ischemic Heart Failure
10/28/2024
6
Urogen Pharma Reports Q3 Loss, Tops Revenue Estimates
11/06/2024
7
Acquisition by Allen Jim L. of 12434 shares of Biocardia at 4.43 subject to Rule 16b-3
11/11/2024
8
BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results
11/13/2024
9
BioCardia, Inc. Q3 2024 Earnings Call Transcript
11/15/2024
10
Biocardia CEO Peter Altman acquires 2,524 in common stock
11/19/2024

Complementary Tools for Biocardia Stock analysis

When running Biocardia's price analysis, check to measure Biocardia's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biocardia is operating at the current time. Most of Biocardia's value examination focuses on studying past and present price action to predict the probability of Biocardia's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biocardia's price. Additionally, you may evaluate how the addition of Biocardia to your portfolios can decrease your overall portfolio volatility.
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges